Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)



CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 2,615 shares of its common stock and an aggregate of 1,307 restricted stock units (RSUs) to three new employees under Blueprint Medicines’ 2020 Inducement Plan.

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *